Abstract
Uncertainty exists about the optimal schedule of adjuvant treatment of breast cancer with aromatase inhibitors and, to our knowledge, no trial has directly compared the three aromatase inhibitors anastrozole, exemestane, and letrozole. We investigated the schedule and type of aromatase inhibitors to be used as adjuvant treatment for hormone receptor-positive early breast cancer. FATA-GIM3 is a multicentre, open-label, randomised, phase 3 trial of six different treatments in postmenopausal women with hormone receptor-positive early breast cancer. Eligible patients had histologically confirmed invasive hormone receptor-positive breast cancer that had been completely removed by surgery, any pathological tumour size, and axillary nodal status. Key exclusion criteria were hormone replacement therapy, recurrent or metastatic disease, previous treatment with tamoxifen, and another malignancy in the previous 10 years. Patients were randomly assigned in an equal ratio to one of six treatment groups: oral anastrozole (1 mg per day), exemestane (25 mg per day), or letrozole (2·5 mg per day) tablets upfront for 5 years (upfront strategy) or oral tamoxifen (20 mg per day) for 2 years followed by oral administration of one of the three aroma...Continue Reading
Citations
Jul 26, 2018·The Journal of Obstetrics and Gynaecology Research·Taisuke MoriJo Kitawaki
May 11, 2019·JAMA Network Open·Alfredo AddeoBishal Gyawali
Feb 26, 2020·Journal of Clinical Medicine·Hsu-Chih ChienWei-Hsuan Lo-Ciganic
Jul 17, 2020·The Journal of Clinical Endocrinology and Metabolism·Tilman D RachnerLorenz C Hofbauer
Nov 10, 2018·Breast Cancer Research and Treatment·Britt I DrögemöllerUNKNOWN CPNDS Clinical Recommendations Group
Feb 3, 2020·Breast Cancer Research and Treatment·Meng LiWenxiong Zhang
Aug 15, 2020·Bone Research·Manni WangXiawei Wei
Sep 22, 2020·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Dane FritzscheKalyan Banda
May 28, 2020·International Journal of Molecular Sciences·Bagora BayalaJean-Marc A Lobaccaro
Dec 29, 2020·Research in Social & Administrative Pharmacy : RSAP·Xuanzi QinBeth A Virnig
Jan 9, 2021·Journal of Experimental & Clinical Cancer Research : CR·Huanhuan HuangChao Ni
Feb 19, 2021·Molecular Pharmaceutics·Anh S LuAliasger K Salem
Jun 3, 2021·Current Oncology·Samitha AndrahennadiShahid Ahmed
May 19, 2021·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Erika Yue LeePeter Vadas
May 29, 2021·Clinical Pharmacology and Therapeutics·Junmei CairnsLiewei Wang
Jul 30, 2021·Bone Research·Manni WangXiawei Wei
Jul 16, 2021·The Breast : Official Journal of the European Society of Mastology·Maria SundAntonis Valachis
Aug 14, 2021·Frontiers in Endocrinology·Tara HyderAdam M Brufsky
Jan 7, 2022·Advances in Therapy·Yongmei WangHaibo Wang